← Leaderboards
Dean E Schraufnagel
University Of Illinois At Chicago
$421,619
Attributed
$421,619
Total exposure
1
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding mix
By agency
NIH$421,619 · 1
By mechanism
U01$421,619 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of Illinois At Chicago
Same institution · by research overlap
- John Varga$15,528,672
- Eileen G Collins$2,453,159
- Mary C Kapella$2,630,968
- Janet L Larson$7,507,069
- Margaret K Covey$2,098,719
Others in their field
Top investigators on “Systemic Scleroderma”
- Eugene W. St Clair · Duke University$24,182,181
- John Varga · University Of Illinois At Chicago$13,781,985
- Carol A Feghali-Bostwick · University Of Pittsburgh At Pittsburgh$11,771,501
- Judith A James · Oklahoma Medical Research Foundation$11,331,322
- Robert M Elashoff · John Wayne Cancer Institute$10,394,671
- Maria Trojanowska · Boston University Medical Campus$10,085,547
Research focus
Systemic SclerodermaRespiratory Disorder ChemotherapyClinical ResearchCooperative StudyCyclophosphamideDiagnostic Respiratory LavageDrug Screening /EvaluationDyspneasFunctional AbilityHuman SubjectHuman Therapy EvaluationInflammationLongitudinal Human StudyLung AlveolusPulmonary Fibrosis /GranulomaQuality Of LifeRespiratory Airway VolumeClinical TrialsPatient Oriented Research
Grant awards (4)
ORAL CYCLOPHOSPHAMIDE VS ORAL PLACEBO IN SSC ALVEOLITIS$134,430
U01 · FY2003 · HL
ORAL CYCLOPHOSPHAMIDE VS ORAL PLACEBO IN SSC ALVEOLITIS$94,751
U01 · FY2002 · HL
ORAL CYCLOPHOSPHAMIDE VS ORAL PLACEBO IN SSC ALVEOLITIS$96,435
U01 · FY2001 · HL
ORAL CYCLOPHOSPHAMIDE VS ORAL PLACEBO IN SSC ALVEOLITIS$96,003
U01 · FY2000 · HL